Horton Capital Management’s UroGen Pharma URGN Stock Holding History

Horton Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$6.7M	Buy	704,749 +20,000	+3%	+$282K	14.94%	2
2021 Q3	$11.5M	Buy	684,749 +56,674	+9%	+$898K	23.27%	2
2021 Q2	$9.59M	Buy	628,075 +8,800	+1%	+$159K	13.04%	2
2021 Q1	$12.1M	Buy	619,275 +228,847	+59%	+$4.86M	20.67%	2
2020 Q4	$7.04M	Buy	390,428 +15,000	+4%	+$314K	8.12%	2
2020 Q3	$7.24M	Sell	375,428 -8,000	-2%	-$181K	6.96%	2
2020 Q2	$10M	Buy	383,428 +131,809	+52%	+$3.22M	7.55%	2
2020 Q1	$4.49M	Buy	251,619 +142,949	+132%	+$3.86M	4.25%	3
2019 Q4	$3.63M	Buy	+108,670	New	+$2.97M	3.53%	3

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Horton Capital Management's URGN Position: Q4 2021 in Review

Horton Capital Management increased its UroGen Pharma (URGN) stake by 2.9% in Q4 2021, buying an estimated $282K and bringing the position to 704,749 shares worth $6.7M. The position accounts for 14.94% of the portfolio, ranked #2.

Horton Capital Management first reported a position in URGN in Q4 2019 and has held it in 9 quarters since. The position peaked at $12.1M in Q1 2021. 78 funds tracked by Wall St. Rank hold URGN as of Q4 2021.

Horton Capital Management held 704,749 shares of UroGen Pharma worth $6.7M as of Q4 2021.
Horton Capital Management bought 20,000 UroGen Pharma shares in Q4 2021, an estimated $282K.
UroGen Pharma made up 14.94% of Horton Capital Management's portfolio in Q4 2021, its #2 holding.
Horton Capital Management first reported a position in UroGen Pharma in Q4 2019 and has held it in 9 quarters since.
Horton Capital Management's UroGen Pharma position peaked at $12.1M in Q1 2021.
78 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2021.

Based on Horton Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.